Gain-of-function genetic alterations of G9a drive oncogenesis.

Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/B-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a histone methyltransferase gene, as well as G9a genomic copy gains in ~26% of human melanomas, which collectively drive tumor growth and an immunologically sterile microenvironment beyond melanoma. Furthermore, the WNT pathway is identified as a key tumorigenic target of G9a gain-of-function, via suppression of the WNT antagonist DKK1. Importantly, genetic or pharmacologic suppression of mutated or amplified G9a using multiple in vitro and in vivo models demonstrate that G9a is a druggable target for therapeutic intervention in melanoma and other cancers harboring G9a genomic aberrations.

[1]  C. Taylor,et al.  High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material , 2019, Scientific Reports.

[2]  F. Prósper,et al.  Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression , 2019, Nature Medicine.

[3]  S. Kummerfeld,et al.  Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1 , 2019, Science.

[4]  R. Margueron,et al.  BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation , 2019, Nature Communications.

[5]  P. Boutros,et al.  MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. , 2018, Cancer cell.

[6]  Kwok-Kin Wong,et al.  EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. , 2018, Cancer cell.

[7]  D. Bishop,et al.  β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas , 2018, The Journal of clinical investigation.

[8]  Frédérick A. Mallette,et al.  Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. , 2018, Cancer cell.

[9]  T. Gajewski,et al.  Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.

[10]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[11]  I. Ng,et al.  Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. , 2017, Journal of hepatology.

[12]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[13]  Sara Weirich,et al.  Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex , 2017, Molecular oncology.

[14]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[15]  T. Graeber,et al.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.

[16]  J. Parker,et al.  An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome , 2016, Nature Medicine.

[17]  B. Maček,et al.  A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib , 2016, EBioMedicine.

[18]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[19]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[20]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[21]  S. Armstrong,et al.  Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.

[22]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[23]  D. Bishop,et al.  25‐Hydroxyvitamin D2/D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort , 2015, International journal of cancer.

[24]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[25]  Ina Kycia,et al.  Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme , 2015, Clinical Epigenetics.

[26]  Pieter Wesseling,et al.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.

[27]  Yunhong Zha,et al.  The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. , 2013, Cell metabolism.

[28]  Xi-Ping Huang,et al.  Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. , 2013, Journal of medicinal chemistry.

[29]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[30]  Jacob D. Jaffe,et al.  Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia , 2013, Nature Genetics.

[31]  Stephen C. J. Parker,et al.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.

[32]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[33]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[34]  L. Liau,et al.  Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.

[35]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[36]  Jun S. Song,et al.  YY1 Regulates Melanocyte Development and Function by Cooperating with MITF , 2012, PLoS genetics.

[37]  Jun Yao,et al.  G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. , 2012, The Journal of clinical investigation.

[38]  Paul Polakis,et al.  Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.

[39]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[40]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[41]  Y. Shinkai,et al.  H3K9 methyltransferase G9a and the related molecule GLP. , 2011, Genes & development.

[42]  David A. Orlando,et al.  The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset , 2011, Nature.

[43]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[44]  Valérie Campagna-Slater,et al.  Structural Biology of Human H3K9 Methyltransferases , 2010, PloS one.

[45]  J. Barrett,et al.  Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[47]  Xiaodong Cheng,et al.  Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation , 2007, Nature.

[48]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[49]  D. Fisher,et al.  MITF: master regulator of melanocyte development and melanoma oncogene. , 2006, Trends in molecular medicine.

[50]  L. Chin,et al.  Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.

[51]  Xing Zhang,et al.  The SET-domain protein superfamily: protein lysine methyltransferases , 2005, Genome Biology.

[52]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[53]  Tsutomu Ohta,et al.  Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. , 2005, Genes & development.

[54]  H. Kato,et al.  G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. , 2002, Genes & development.

[55]  Kazuhiro Takahashi,et al.  Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-3a* , 2000, The Journal of Biological Chemistry.

[56]  D. Raible,et al.  Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. , 2000, Genes & development.

[57]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[58]  T. Kouzarides,et al.  CBP/p300 as a co-factor for the Microphthalmia transcription factor , 1997, Oncogene.

[59]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .